SEATTLE--(BUSINESS WIRE)--Apr. 3, 2017--
Omeros Corporation (NASDAQ: OMER) today announced that Gregory A.
Demopulos, M.D., chairman and chief executive officer, will present at
the 16th Annual Needham Healthcare Conference in New York
City this week. The presentation is scheduled for Wednesday, April 5,
2017 at 12:10 p.m. EDT.
The presentation will be webcast. The live and archived webcasts can be
accessed on the “Events” page of the company’s website at www.omeros.com.
About Omeros Corporation
Omeros is a biopharmaceutical company committed to discovering,
developing and commercializing both small-molecule and protein
therapeutics for large-market as well as orphan indications targeting
inflammation, coagulopathies and disorders of the central nervous
system. Part of its proprietary PharmacoSurgery® platform,
the company’s first drug product, OMIDRIA® (phenylephrine and
ketorolac injection) 1% / 0.3%, was broadly launched in the U.S. in
April 2015. OMIDRIA is the first and only FDA-approved drug (1) for use
during cataract surgery or intraocular lens (IOL) replacement to
maintain pupil size by preventing intraoperative miosis (pupil
constriction) and to reduce postoperative ocular pain and (2) that
contains an NSAID for intraocular use. In the European Union, the
European Commission has approved OMIDRIA for use in cataract surgery and
lens replacement procedures to maintain mydriasis (pupil dilation),
prevent miosis (pupil constriction), and to reduce postoperative eye
pain. Omeros has clinical-stage development programs focused on:
complement-associated thrombotic microangiopathies; complement-mediated
glomerulonephropathies; Huntington’s disease and cognitive impairment;
and addictive and compulsive disorders. In addition, Omeros has a
proprietary G protein-coupled receptor (GPCR) platform, which is making
available an unprecedented number of new GPCR drug targets and
corresponding compounds to the pharmaceutical industry for drug
development, and a platform used to generate antibodies.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170403005568/en/
Source: Omeros Corporation
Cook Williams Communications, Inc.
Jennifer Cook Williams
and Media Relations